anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject aqueous solution, capable of suppressing the deterioration in viscosity even by preservation for a long period and stabilized in the viscosity by including hyaluronic acid (salt) and a viscosity stabilizer therein. SOLUTION: This eye drop aqueous solution comprises (A) at least one selected from the group consisting of hyaluronic acid and its salt and (C) at least one selected from the group consisting of a polyol (preferably ethylene glycol, glycerol or polyvinyl alcohol, etc.), a polycarboxylic acid (preferably citric acid or a carboxyvinyl polymer), a polycarboxylate and a glucide (preferably sorbitol, trehalose, etc.) as a viscosity stabilizer and has 2-2,000mm<2> /S viscosity thereof. The concentration of the ingredient A is preferably 0.1-5.0mg/mL and that of the ingredient B is preferably 0.5-50.0mg/mL. Thereby, an eye drop solution capable of manifesting promoting actions on the extension of an anterior epithelial layer of the cornea and preventing actions on the drying can be expected.
Purpose: Assess the efficacy and safety of valproic acid (VPA) for delirium and agitation in the intensive care unit (ICU) as compared to the use of other antipsychotics. Materials and Methods: This was a retrospective cohort study of patients treated for delirium and agitation in the ICU. Patients were included if they had a Richmond Agitation-Sedation Scale ≥2 and Confusion Assessment Method for the ICU positive. Patients were split into two groups based on their VPA exposure. The primary outcome was delirium free days. Secondary outcomes included agitation free days, ICU length of stay (LOS), mechanical ventilation duration, and mortality. Results: One hundred eight patients were included, 49 patients in the VPA group and 59 patients in the control group. Baseline characteristics were similar between groups. There was no significant difference in the primary outcome (difference -.15, 95% CI: 0.63-.93, P = .70). There were no significant differences in agitation-free days, mortality, mechanical ventilation duration, or ICU LOS. Conclusions: Our findings suggest that VPA is associated with similar delirium and agitation-free days compared to other non-VPA medications, with some adverse effects. Larger prospective studies are needed to validate the routine use of VPA in this setting.
Inclusion criteria for the benign/cystectomy cohort includes bladder cancer planned to be treated with removal of the urinary bladder and prostate (cystoprostatectomy). The benign/cystectomy cohort will include a total of 25 subjects.
FIELD: medicine. ^ SUBSTANCE: invention refers to cosmetic industry. A composition is used for personal care and contains dihydroxypropyltri(C1-C3alkyl)ammonium salt in a carrier. The composition is packed for consumer delivery and includes an insert printed on the package or attached thereto and specifying the local application of the composition on skin, hair or oral mucosa. Preferentially, dihydroxypropyltrimonium chloride is used as said salt. ^ EFFECT: salt has an effect of a moisturiser both at high, and at low relative humidity. ^ 2 cl, 12 ex, 12 tbl
NEW MATERIAL:N-Cyano- N-methyl- N'-( 4-methyl-5-imidazolylmethyl )-N''-mercaptoethylguanidine shown by the formula I . USE:A useful compound standing in pharmaceutically important fields. Useful for synthesizing cimetidine, an antiulcer having strong inhibitory action on secretion of acid in the stomach. PROCESS:N-Cyano-N'-methyl-N-( 4-methyl-5-imidazolylmethyl )-S-methyl-isothiourea shown by the formula II is reacted with cysteamine shown by the formula III or its hydrochloride in an organic polar solvent such as preferably methanol, ethanol, etc. in the presence of an alkali metal base such as sodium hydride, etc. in an inert atmosphere at room temperature to give a compound shown by the formula I . The compound shown by the formula II is synthesized by reacting a compound shown by the formula IV with a compound shown by the formula Vin an organic polar solvent in the presence of an organic base.
Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
PROBLEM TO BE SOLVED: To obtain a hair-conditioning composition containing a cationic surfactant and a high mol.wt. silicone emulsion and excellent in effects for giving gloss, smoothness, flexibility and dry touch to hair. SOLUTION: This hair-conditioning composition contains a cationic surfactant in an amount of 0.01-10wt.% and a high mol.wt. silicone emulsion represented by the formula [R1 is methyl, phenyl; R2 is methyl, OH, (m) is 800-5000], obtained by an emulsion polymerization method and having an average particle diameter of 0.25-30μm in an amount of 0.01-10wt.% as the pure content of the high mol.wt. silicone. The cationic surfactant is good in affinity and adsorbability on hair, can give smoothness and flexibility to the hair and is preferably a mono long chain alkyl type quaternary ammonium salt such as stearyltrimethylammonium chloride, etc. The high mol.wt. silicone emulsion can give gloss and dry touch to the hair, is stable because of being an emulsion, and is good in adhesion to the hair, because the average particle diameter of the emulsion particles is moderate.
The present invention provides compositions and methods for transplanting cells into a solid organ by an implantation strategy. These methods and compositions are useful for repairing diseased organs or for modeling disease states in experimental hosts. The method involves attaching a patch implant, a "bandage-like" covering, to the surface of a tissue or organ, the "bandage-like" covering containing epithelial cells as well as mesenchymal cells during supportive early lineage. The cells are incorporated into a gel-forming biomaterial that is prepared under serum-free, defined conditions that collectively support the sternness of the donor cells. The implant is covered with a biodegradable, biocompatible, bioresorbable substrate for immobilizing the implant at a target site. The cells in the implant migrate to and throughout the tissue such that they are evenly dispersed within the recipient (host) tissue within two weeks. The mechanism of donor cell implantation and integration into the organ or tissue involves multiple membrane-associated and secreted forms of MMPs.
The Asthma Program will consist of six screenings and three camps each year, for two consecutive years. Screenings will be conducted in areas where populations are known to be at increased risk for asthma and its complications, such as inner-city, lower socioeconomic, African-American populations. Screenings will be conducted at churches or schools in these areas one month prior to each camp in an effort to identify children with undiagnosed or uncontrolled asthma and refer them to the camps. Camps will also be conducted in areas where populations are known to be at increased risk for asthma and its complications to improve ease of access. Asthma and smoking cessation education will be provided at each camp to children and caregivers. Baseline data will be collected at each camp and assessed. Longitudinal clinical outcomes will be assessed in children attending multiple camps.
This invention reveals the beneficial use of vitamin E tocotrienols for inhibition of  chlamydial  infections.  Chlamydial  infection levels in mouse macrophages treated with tocotrienol were decreased >50%, with concomitant aberrant pathogen development. The number of large and small inclusions in tocotrienol-versus-control cells was decreased 3-fold and 2-fold, respectively. When treated with delta tocotrienol,  Chlamydia  in human lymphocytes was inhibited by at least 2.6-fold in 1.5 days. Dietary delta tocotrienol inhibited  Chlamydia  infection and persistence in hypercholesterolemic patients with a corresponding drop in LDL. These studies demonstrate that tocotrienol lowers cholesterol, thus preventing or diminishing the cholesterol hijacking by  Chlamydia  obligatory for its infectivity and replication. Therefore, hypolipidemic agents used to treat cardiovascular diseases, metabolic syndrome, and diabetes are used as monotherapies, or in combination with tocotrienol to treat  Chlamydia.
<P>PROBLEM TO BE SOLVED: To provide a method which is inexpensive and packages a solution containing a protein, and also to provide a container which is obtained.  <P>SOLUTION: A flexible polymeric container holds albumin. The container (12) is made of a sheet of a flexible polymeric film (34) formed into a bag. The flexible polymeric container has a cavity which is surrounded by a first wall, an opposing second wall, and seals about a periphery of these first and second walls. The seals join the inner parts of the opposing first and second walls, and create a fluid-tight chamber for storing the albumin with a certain concentration in the cavity of the container. The method for packaging the albumin protein in the flexible polymeric container is provided. A flexible polymeric material is converted into the bags, and a certain amount of the albumin is filled into the bag with a filling appliance (44) and the albumin is stored in the bag by sealing the sealing area of the bag.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant 1\. 9 11. The recipient of the citrated blood product should be monitored for the signs and symptoms of citrate toxicity 1\. 9 11. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions that are characterized by hypotension and possible cardiac arrhythmia 1\. 9 11. Citrate toxicity may occur more frequently in patients that are hypothermic 10, have impaired liver or renal function 10, or have low calcium levels because of an underlying disease 9.
Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients' characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice.
Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
Assisted reproductive technology and stimulated conception have led to an increase in the prevalence of high order multifetal pregnancies (MFPs) in recent times. MFPs are associated with high maternal and fetal complications. Fetal mortality and morbidity are due to complications of prematurity. Prevalence of pregnancy induced hypertension, pre-eclampsia, eclampsia, antepartum hemorrhage, post-partum hemorrhage, gestational diabetes and difficult deliveries are more in mother with MFP. Embryo/Fetal reduction in high order MFPs helps in prolongation of gestation. Multifetal pregnancy reduction (MFPR) is secondary prevention of the risks associated with MFP. Trans-abdominal intracardiac injection of KCl is a simple, safe and effective technique for MFPR. We are among the first few centers in Nepal doing MFPR. In this study, we are sharing our initial experience of the procedure.
A process and unit for determining an estimate for a respiratory signal. Measured values are received, and a sum signal is generated, which is a superimposition of the respiratory signal to a cardiogenic signal. The unit detects heartbeats, and a respective heartbeat time period for each. An intermediate signal is calculated by compensating the influence of the cardiac activity on the sum signal. The unit determines an attenuation signal, which is an indicator of the average time curve of the contribution of the cardiogenic signal to the intermediate signal in a predefined reference heartbeat time period. An intermediate signal section is generated as a section of the intermediate signal in a heartbeat time period and intermediate signal sections are mapped to the reference heartbeat time period. The estimated respiratory signal is calculated with the use of the mapped intermediate signal sections and of the attenuation signal.
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
BACKGROUND: The purpose of this study was to determine if the presence of a standing Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, psychiatric diagnosis is associated with worse outcomes for patients who develop a confirmed fracture-related infection (FRI).
MATERIALS AND METHODS: Included patients had open or closed fractures managed with internal fixation and had confirmed FRIs. Baseline demographics, injury information, and outcomes were collected via chart review. All patients who had a diagnosis of psychiatric illness, which included depression, bipolar disorder, anxiety disorder, and schizophrenia, were identified. Patients with and without a psychiatric diagnosis were statistically compared.
RESULTS: Two hundred eleven patients were diagnosed with a confirmed FRI. Fifty-seven (27.0%) patients had a diagnosis of a psychiatric illness at the time of FRI diagnosis. Patients with a psychiatric diagnosis had a higher rate of smoking (56% vs 40%, P=.039) and drug use (39% vs 19%, P=.004) and a higher American Society of Anesthesiologists (ASA) classification (2.35±1.33 vs 1.96±1.22, P=.038); however, there were no other demographic differences. Clinical outcomes also did not differ between the groups, as patients with an FRI and a psychiatric diagnosis had a similar time to FRI diagnosis, similar confirmatory FRI characteristics, and a similar rate of reoperation. Furthermore, there was no difference between patients with FRI with and without a psychiatric diagnosis regarding rate of infection resolution (89% vs 88%, P=.718) or time to final follow-up (20.13±24.93 vs 18.11±21.81 months, P=.270).
CONCLUSION: The presence of a psychiatric diagnosis does not affect clinical outcomes in the patient population with FRI. This is the first study exploring the impact of psychiatric illness on patient outcomes after a confirmed FRI diagnosis. [Orthopedics. 2024;47(4):198-204.].
We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
The invention includes saponin-containing compositions, wipes impregnated with these compositions, and related methods. Specifically, the invention includes a cleansing and deodorizing composition that includes a saponin; a deodorizer; cyclodextrin and a solvent. The saponin may be derived from botanical sources, such as, for example,  Sapindus mukorossi  or  trifoliatus.  Also included are textiles that are impregnated with the composition of the invention. Such textiles may be, for example, made of biodegradable materials. The invention also includes related methods of use and treatment.
The invention belongs to the field of medicines and particularly relates to a pharmaceutical composition for treating asthma and a preparation method thereof. The pharmaceutical composition is prepared by combining active ingredients of tripterygium wilfordii or extract thereof and licorice or extract thereof. The weight ratio of active pharmaceutical ingredients is as follows: 80-100 portions of tripterygium wilfordii and 3-6 portions of licorice. By applying the pharmaceutical composition provided by the invention, the purpose of treating asthma by replacing glucocorticoid can be achieved so as to realize the reduction or non-use of hormone, and reduce adverse reactions brought about by the long-term use of the glucocorticoid. Moreover, by adopting the compatibility of the tripterygium wilfordii and the licorice, the toxic and side effects of the tripterygium wilfordii can be reduced, and the synergistic effect also can be realized. The pharmaceutical composition has a stable and controllable curative effect.
The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
Iron deficiency is the main cause of anaemia, especially in premenopausal due to heavy menstrual bleeding. In this case report, an asymptomatic woman presented with a haemoglobin level of 3.9 mmol/l. Due to uterine fibroids, she was scheduled for myomectomy, and she was treated with IV iron. Fourteen days post infusion her haemoglobin level was 6.3 mmol/l. This highlights the importance of screening women for heavy menstrual bleeding causing iron deficiency, and encourage at-risk women to take iron supplements. Furthermore, one should be aware of IV iron therapy as an alternative to blood transfusion in treating iron deficiency anaemia.
In addition to colorectal cancer and metabolic syndrome, regular yogurt consumption has shown promise in improving skin inflammation. In this study, we investigated the effects and possible mechanisms of yogurt on imiquimod-induced psoriasis-like inflammation in mice. After oral administration with yogurt (18 or 36 g/kg) and/or its main metabolite lactate (250 or 500 mg/kg) for 3 days, the mice were treated with a topical dose of 62.5 mg of imiquimod (IMQ) cream for seven consecutive days. Data showed that yogurt and lactate treatment significantly reduced the severity of psoriasis-like skin lesions, excessive keratinocyte proliferation, and immune cell infiltration. Mechanistically, we found that the genetic deficiency of the lactate receptor GPR81 aggravated psoriasis-like features in mice. Activation of the lactate/GPR81 axis inhibited the degradation of IκBα, prevented the nuclear translocation of histone deacetylase 3 (HDAC3) in macrophages, and thus constrained skin inflammation. Overall, these findings suggest that yogurt consumption effectively protects against experimental psoriasis and targeting the lactate/GPR81 signaling axis could be a promising approach for psoriasis inflammation management.
ARM III: Patients receive placebo PO nightly for 12 weeks in the absence of unacceptable toxicity. Patients may choose to enroll in an additional 12 weeks of treatment. Patients undergo CT scan and monthly collection of blood samples on study.